Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.34 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2251395 | 1.00 | NPC1 (0.40) | NPC1RAB9ATNFALOX15KDM4E | |
| SCHEMBL29388571 | 1.00 | NPC1 (0.40) | NPC1RAB9ATNFALOX15KDM4E | |
| SCHEMBL29471925 | 1.00 | NPC1 (0.40) | NPC1RAB9ATNFALOX15KDM4E | |
| Formic Acid SCHEMBL2252830 | 0.96 | NPC1 (0.37) | NPC1RAB9ATNFALOX15KDM4E | |
| Formic Acid SCHEMBL19630437 | 0.95 | NPC1 (0.37) | NPC1RAB9ATNFALOX15KDM4E | |
| SCHEMBL20469302 | 0.89 | NPC1 (0.39) | NPC1RAB9ATNFALOX15KDM4E | |
| SCHEMBL19603302 | 0.89 | ALOX15 (0.34) | NPC1RAB9ATNFALOX15KDM4E | |
| SCHEMBL27432117 | 0.89 | NPC1 (0.39) | NPC1RAB9ATNFALOX15KDM4E | |
| SCHEMBL27432120 | 0.89 | NPC1 (0.39) | NPC1RAB9ATNFALOX15KDM4E | |
| SCHEMBL7857212 | 0.89 | TNF (0.39) | NPC1RAB9ATNFALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4467143-B1 | METHOD FOR PREPARING 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260007679-A1 | METHODS OF TREATING CANCER USING 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE | CELGENE CORP (US) | 2026-01-08 | — | — | US | disclosed |
| US-12510533-B2 | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile | CELGENE CORPORATION (US) | 2025-12-30 | — | — | US | disclosed |
| US-12318452-B2 | Degraders of WEE1 kinase | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250032502-A1 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | CELGENE CORPORATION (US) | 2025-01-30 | — | — | US | disclosed |
| EP-4467143-A2 | 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE AS ANTIPROLIFERATIVE COMPOUND | Celgene Corporation (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240366593-A1 | ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USE | SIGNAL PHARMACEUTICALS, LLC | 2024-11-07 | — | — | US | disclosed |
| EP-3651766-B1 | 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE AS ANTIPROLIFERATIVE COMPOUND | CELGENE CORP (US) | 2024-09-11 | — | — | EP | disclosed |
| US-12064437-B2 | Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies | CELGENE CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| US-12053466-B2 | Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use | CELGENE CORPORATION (US) | 2024-08-06 | — | — | US | disclosed |
| US-8518972-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518972-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518972-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2536706-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2012-12-26 | — | — | EP | disclosed |
| CN-102822165-A | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORP | 2012-12-12 | — | — | CN | disclosed |
| WO-2011100380-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011100380-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366593-A1 | ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USE | CD4, CD2, CD22 | NPC1 3631/4885RAB9A 3280/4885TNF 1651/4885 |
| US-20260007679-A1 | METHODS OF TREATING CANCER USING 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE | MALT1, BCL6, BCL9 | NPC1 718/4885RAB9A 3088/4885TNF 3112/4885 |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP3A4, CYP3A43 | NPC1 91/4885RAB9A 3351/4885TNF 4590/4885 |
| US-12510533-B2 | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile | IKZF1, IKZF3, IKZF2 | NPC1 2203/4885RAB9A 3933/4885TNF 1900/4885 |
| US-12318452-B2 | Degraders of WEE1 kinase | WEE1, WEE2, PPME1 | NPC1 3966/4885RAB9A 2805/4885TNF 3958/4885 |
| US-20250032502-A1 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | IKZF3, IRF2BP2, IRF3 | NPC1 2883/4885RAB9A 4696/4885TNF 1116/4885 |
| US-12053466-B2 | Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use | CD4, CD2, CD22 | NPC1 3631/4885RAB9A 3280/4885TNF 1651/4885 |
| US-12064437-B2 | Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies | IKZF3, IRF2BP2, IRF3 | NPC1 2883/4885RAB9A 4696/4885TNF 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.